Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation. Dr Nicole van der Weerden will be giving an in-person presentation of this update at 11am on June 26th in Melbourne at Level 21, 333 Collins Street (offices of Arnold Bloch Liebler).
Some shareholders have indicated that they wish to buy or sell Hexima Shares. Hexima has been contacted by two shareholders, including an entity controlled by G.F. Dan O’Brien, willing to purchase Hexima shares at a price of $0.08. Hexima has appointed Bell Potter to co-ordinate a secondary sale process of Hexima Shares. Any parties wishing to buy or sell shares should contact Bell Potter (see below for contact details).
Any shareholders wishing to trade shares will be required to become clients of Bell Potter. Please note that this will not commit you to any further dealings with Bell Potter. Shareholders wishing to finalise transactions prior to 30 June 2017 will also need to meet Bell Potter’s internal deadlines, including providing client paperwork by 21 June 2017.
We look forward to keeping you updated as we progress HXP124 into the clinic.
Nicole van der Weerden